Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

5 trials in Phase 3/4

Results Transparency

33%

4 of 12 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2
4(26.7%)
N/A
4(26.7%)
Phase 3
4(26.7%)
Phase 1
2(13.3%)
Phase 4
1(6.7%)
15Total
Phase 2(4)
N/A(4)
Phase 3(4)
Phase 1(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT05205811Phase 3Completed

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

Role: lead

NCT06554873Phase 3Completed

Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders

Role: lead

NCT05994703Phase 2Completed

Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine

Role: lead

NCT04188197Not ApplicableCompleted

Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes

Role: lead

NCT06088862Phase 3Terminated

Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

Role: lead

NCT06072547Not ApplicableRecruiting

Effect of Flavored on!® Nicotine Pouch Products on Smoking Behaviors: a SMART Study

Role: collaborator

NCT05855343Not ApplicableCompleted

Exploratory Study of Switching From Combustible Cigarettes to the BIDI E-cigarette

Role: lead

NCT04933916Phase 1Terminated

Study of EMB-001 as a Potential Smoking Cessation Treatment

Role: collaborator

NCT04188106Phase 4Completed

Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment

Role: lead

NCT04388319Phase 3Completed

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

Role: lead

NCT04210180Phase 2Completed

Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

Role: lead

NCT02870218Phase 2Completed

Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use

Role: lead

NCT04826549Completed

A Comparison of Exhaled Carbon Monoxide Measurements Using the iCOquit Smokerlyzer and Vitalograph Breath CO Monitor vs Carboxyhemoglobin From Venous Samples While Validating a Mobile Research Application

Role: lead

NCT04523948Unknown

Comparative Tobacco Interventions for Individuals With Severe and Persisting Behavioral Health Disorders

Role: lead

NCT03596034Not ApplicableCompleted

A Study to Characterize Puff Topography With Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers

Role: collaborator

NCT04868253Phase 2Unknown

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Role: lead

NCT02906995Phase 1Completed

Pharmacokinetics of Nicotine Sublingual Tablets Versus Nicorette Lozenge in Healthy Smokers

Role: collaborator

All 17 trials loaded